Florence Joly
Prof Florence Joly is an expert in Oncology at Centre François Baclesse (France). As of October 2026, ScienceLeadR ranks Florence Joly in the top 1% of experts worldwide for Urogenital Neoplasms, Ovarian Neoplasms and Gonadal Disorders. Florence Joly has authored 680 publications, the most recent in 2026, and is an investigator in 135 clinical trials, 36 of them ongoing. SLR score: 4,281 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Gynecology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1995 - 2026
Number : 680
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Degree of self-certainty is related to the association between cognitive flexibility and anxiety following breast cancer treatments. PMID 42831828 — breast neoplasms, neuropsychological tests, neoplasms, breast, therapeutics, nervous system diseases, cognitive flexibility | Neuropsychology | 2026 | 0 |
| Distinct sleep and rest-activity profiles according to adjuvant treatment exposure in women treated for breast cancer. PMID 42830446 — breast neoplasms, sleep, neoplasms, actigraphy, fatigue, breast, therapeutics | Oncologist | 2026 | 0 |
| Prospective memory in breast cancer survivors treated with endocrine therapy: findings from an ecological virtual reality task. PMID 42770237 — neuropsychology, virtual reality, cancer survivors, breast neoplasms, neoplasms, drug therapy, breast, cognition disorders, therapeutics, memory, chemotherapy | Arch Clin Neuropsychol | 2026 | 0 |
| Clinical outcomes and prognostic factors in advanced high-grade platinum-resistant ovarian carcinoma: evidence from the ESME real-world cancer database. PMID 42660771 — progression-free survival, paclitaxel, ovary, genital neoplasms, female, doxorubicin, neoplasms, multiple chronic conditions, bevacizumab, drug therapy, ovarian neoplasms, prognosis, chemotherapy | Int J Gynecol Cancer | 2026 | 0 |
| Methodology of analysis of cognitive impairment in longitudinal randomized clinical trials in oncology: a scoping review. PMID 42663721 — sample size, neoplasms, cognitive dysfunction, cognition disorders, therapeutics, palliative care, cognition | Support Care Cancer | 2026 | 0 |
Clinical Studies 135
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
36 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| CARE1 FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA 2023-503317-29-00 — cells, carcinoma, renal cell, therapeutics, carcinoma | Phase 3 | Recruiting | 2024 |
| A MULTICENTER SEEKING SIGNAL RANDOMISED OPEN LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS 2024-514032-25-00 — uterine cervical neoplasms, neoplasms, nivolumab | Phase 2 | Active not recruiting | 2024 |
| Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator s Choice in Chemotherapy na ve Metastatic Castration resistant Prostate Cancer 2025-520555-89-00 — neoplasms, prostate, drug therapy, prostatic neoplasms, castration, therapeutics, chemotherapy | Phase 3 | Recruiting | 2025 |
| A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK 2870 022) 2023-508015-23-00 — safety, ovary, neoplasms, bevacizumab, drug therapy, maintenance, ovarian neoplasms, therapeutics, chemotherapy | Phase 3 | Not yet recruiting | 2025 |
| A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER 2 ) 2025-522855-25-00 — urinary bladder, carcinoma, transitional cell, urinary bladder neoplasms, cells, safety, urinary tract, neoplasms, neoplasm metastasis, carcinoma | Phase 3 | Not yet recruiting | 2026 |
LeadR Networks
Main global connection map